Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Avita Taps Sinopharm To Ramp-Up China Sales Of ReCell "Spray-On-Skin"

Executive Summary

Avita Medical has awarded Sinopharm with exclusive rights to distribute across China ReCell, an autologous cell harvesting device that creates a cellular suspension made from the patient’s own skin for use in advanced wound care and the treatment of skin defects. This "spray-on-skin" can be used in conjunction with all other key wound care approaches and is currently in a multi-center pivotal trial to obtain US FDA premarket approval, which is expected in Q3 2017.



Related Companies